Rocket Pharma Q2 net loss narrows; co cuts 30% of workforce

Rocket Pharmaceuticals

07/08/2025 21:09

Overview

Rocket Pharma reports Q2 net loss of $68.9 mln, down from $69.6 mln yr ago

Company restructures, cutting 30% of workforce to focus on AAV gene therapy

Outlook

Rocket expects cash resources to fund operations into Q2 2027

Result Drivers

RESTRUCTURING - Co reduces workforce by 30% to focus on AAV cardiovascular gene therapy platform

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$68.90 mln
Q2 Basic EPS
-$0.62


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $8.50, about 64.5% above its August 6 closing price of $3.02

Press Release: ID:nBw3c1nkGa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)